Rustin G J, van der Burg M E, Berek J S
Charing Cross Hospital, London, UK.
Ann Oncol. 1993;4 Suppl 4:71-7.
There is a need to discover new tumour markers for ovarian carcinoma as well to delineate how the best currently available marker, CA 125 should be used.
This review examines the potential of growth factors and cytokines such as M-CSF, IL-6 and IL-10 as tumour markers as well as the over expression of oncogenes such as HER-2/neu in ovarian cancer. The major part of this review critically examines the uses of serum CA 125.
Precise definitions for progression of ovarian carcinoma during treatment and on follow up were produced from studying a group of 71 and tested in a separate group of 164 women with ovarian carcinoma. They were found to predict progression with a false positive rate of only 8%. Definitions for response according to CA 125 are proposed.
CA 125 remains the best tumour marker for ovarian carcinoma. It is not sensitive enough for screening and lack of specificity reduces its diagnostic accuracy. It's main role is in monitoring response to therapy and detecting tumour recurrence early and more reliably than by other methods.
需要发现新的卵巢癌肿瘤标志物，并明确如何使用目前最好的标志物——CA 125。
本综述研究了诸如M-CSF、IL-6和IL-10等生长因子和细胞因子作为肿瘤标志物的潜力，以及卵巢癌中HER-2/neu等癌基因的过表达情况。本综述的主要部分对血清CA 125的用途进行了批判性研究。
通过对71名患者的研究得出了卵巢癌治疗期间及随访过程中病情进展的精确定义，并在另外164名卵巢癌女性患者中进行了验证。结果发现这些定义预测病情进展的假阳性率仅为8%。文中还提出了根据CA 125判断疗效的定义。
CA 125仍然是卵巢癌最好的肿瘤标志物。它用于筛查时灵敏度不足，缺乏特异性降低了其诊断准确性。其主要作用是监测治疗反应，比其他方法能更可靠地早期检测肿瘤复发。
